Alpine Immune Sciences (NASDAQ:ALPN) Rating Lowered to Neutral at Wedbush

Alpine Immune Sciences (NASDAQ:ALPN - Get Free Report) was downgraded by equities research analysts at Wedbush from an "outperform" rating to a "neutral" rating in a report released on Thursday, MarketBeat Ratings reports.

Several other equities analysts have also issued reports on the company. Royal Bank of Canada reiterated a "sector perform" rating and issued a $65.00 price target (up previously from $41.00) on shares of Alpine Immune Sciences in a research note on Thursday. Wolfe Research reiterated a "peer perform" rating on shares of Alpine Immune Sciences in a report on Thursday. HC Wainwright raised their price objective on Alpine Immune Sciences from $32.00 to $50.00 and gave the company a "buy" rating in a report on Tuesday, March 19th. Guggenheim started coverage on Alpine Immune Sciences in a research report on Tuesday. They set a "buy" rating and a $55.00 price objective on the stock. Finally, Oppenheimer reiterated an "outperform" rating and issued a $44.00 target price (up from $33.00) on shares of Alpine Immune Sciences in a research report on Tuesday, March 19th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $48.50.

Alpine Immune Sciences Stock Up 36.9 %

ALPN opened at $64.40 on Thursday. Alpine Immune Sciences has a twelve month low of $6.71 and a twelve month high of $64.45. The stock has a market capitalization of $4.22 billion, a price-to-earnings ratio of -100.63 and a beta of 1.14. The company has a 50-day simple moving average of $35.68 and a 200 day simple moving average of $22.60.

Alpine Immune Sciences (NASDAQ:ALPN - Get Free Report) last issued its quarterly earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.47. The company had revenue of $30.85 million during the quarter, compared to the consensus estimate of $6.90 million. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. Sell-side analysts anticipate that Alpine Immune Sciences will post -1.76 EPS for the current fiscal year.

Institutional Investors Weigh In On Alpine Immune Sciences

Several institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its stake in Alpine Immune Sciences by 23.4% during the 1st quarter. JPMorgan Chase & Co. now owns 8,947 shares of the biotechnology company's stock worth $80,000 after buying an additional 1,697 shares during the period. Vanguard Group Inc. raised its position in Alpine Immune Sciences by 1.4% in the first quarter. Vanguard Group Inc. now owns 707,598 shares of the biotechnology company's stock worth $6,347,000 after acquiring an additional 9,844 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Alpine Immune Sciences by 7.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 32,417 shares of the biotechnology company's stock valued at $291,000 after purchasing an additional 2,294 shares during the last quarter. State Street Corp raised its stake in shares of Alpine Immune Sciences by 7.1% in the first quarter. State Street Corp now owns 220,621 shares of the biotechnology company's stock valued at $1,979,000 after buying an additional 14,609 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in Alpine Immune Sciences by 70.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 22,850 shares of the biotechnology company's stock valued at $205,000 after acquiring an additional 9,471 shares during the period. Institutional investors own 75.17% of the company's stock.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development.